Susquehanna Portfolio Strategies LLC decreased its position in shares of HealthEquity, Inc. (NASDAQ:HQY – Free Report) by 33.9% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,999 shares of the company’s stock after selling 12,821 shares during the period. Susquehanna Portfolio Strategies LLC’s holdings in HealthEquity were worth $2,041,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also bought and sold shares of HQY. Cape Investment Advisory Inc. purchased a new stake in HealthEquity in the fourth quarter worth about $27,000. Rise Advisors LLC purchased a new stake in HealthEquity in the first quarter worth about $28,000. McGlone Suttner Wealth Management Inc. purchased a new stake in HealthEquity in the fourth quarter worth about $29,000. YHB Investment Advisors Inc. purchased a new stake in HealthEquity in the first quarter worth about $40,000. Finally, Fidelis Capital Partners LLC purchased a new stake in HealthEquity in the first quarter worth about $42,000. Institutional investors own 99.55% of the company’s stock.
HealthEquity Price Performance
HQY stock traded up $0.14 during midday trading on Monday, reaching $76.63. The stock had a trading volume of 123,419 shares, compared to its average volume of 603,270. The company’s fifty day simple moving average is $81.42 and its 200 day simple moving average is $79.35. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.44. The company has a market cap of $6.67 billion, a price-to-earnings ratio of 83.14, a price-to-earnings-growth ratio of 1.29 and a beta of 0.57. HealthEquity, Inc. has a 52-week low of $61.32 and a 52-week high of $88.26.
Wall Street Analyst Weigh In
Several analysts have commented on the stock. BTIG Research increased their price target on shares of HealthEquity from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, March 20th. JPMorgan Chase & Co. increased their price target on shares of HealthEquity from $86.00 to $108.00 and gave the company an “overweight” rating in a research report on Tuesday, April 2nd. Robert W. Baird upped their price objective on shares of HealthEquity from $98.00 to $104.00 and gave the company an “outperform” rating in a report on Tuesday, June 4th. JMP Securities upped their price objective on shares of HealthEquity from $101.00 to $105.00 and gave the company a “market outperform” rating in a report on Tuesday, June 4th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $92.00 price objective on shares of HealthEquity in a report on Tuesday, June 4th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, HealthEquity presently has an average rating of “Moderate Buy” and a consensus price target of $101.67.
Get Our Latest Research Report on HealthEquity
Insiders Place Their Bets
In related news, Vice Chairman Stephen Neeleman sold 400 shares of the firm’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $85.00, for a total transaction of $34,000.00. Following the completion of the sale, the insider now directly owns 90,515 shares of the company’s stock, valued at approximately $7,693,775. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other HealthEquity news, Vice Chairman Stephen Neeleman sold 400 shares of HealthEquity stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $85.00, for a total value of $34,000.00. Following the completion of the transaction, the insider now directly owns 90,515 shares of the company’s stock, valued at approximately $7,693,775. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Jon Kessler sold 32,326 shares of HealthEquity stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $82.83, for a total value of $2,677,562.58. Following the completion of the transaction, the chief executive officer now directly owns 232,176 shares of the company’s stock, valued at $19,231,138.08. The disclosure for this sale can be found here. Insiders sold 42,511 shares of company stock valued at $3,519,346 in the last three months. 2.20% of the stock is currently owned by insiders.
HealthEquity Profile
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Articles
- Five stocks we like better than HealthEquity
- Pros And Cons Of Monthly Dividend Stocks
- Major Gaming Stock to Watch: Why It’s a Safe Bet Now
- What are earnings reports?
- AI-Powered Insurance Disruptor: This Stock Is a Growth Machine
- Bank Stocks – Best Bank Stocks to Invest In
- Why Consumer Stock Is Citigroup Analysts’ Top Choice Right Now
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.